子宮內膜癌市場規模、佔有率和成長分析（按癌症類型、治療方法、診斷方法、分期、最終用途和地區分類）—產業預測，2026-2033年

預計到 2024 年，全球子宮內膜癌市場規模將達到 301 億美元，到 2025 年將成長至 315.7 億美元，到 2033 年將成長至 463 億美元，預測期（2026-2033 年）的複合年成長率為 4.9%。

由於發病率上升、公眾意識提高以及醫療基礎設施的完善，全球子宮內膜癌市場正經歷強勁成長。診斷方法的創新，特別是分子譜分析和基因檢測技術的進步，使得精準化和個人化治療策略成為可能。標靶治療、免疫療法和聯合療法的出現，透過提高療效並減少副作用，促進了市場擴張。此外，基因組分析和液態生物檢體等技術的進步也為早期檢測和個人化治療方案提供了支持。然而，高昂的治療費用、先進醫療設施的匱乏以及對有效早期檢測技術的需求，仍然是亟待解決的關鍵挑戰，以減輕全球子宮內膜癌的負擔。

全球子宮內膜癌市場促進因素

推動全球子宮內膜癌市場成長的關鍵因素是全球子宮內膜癌發生率的不斷上升。作為最常見的婦科癌症之一，子宮內膜癌的發生率持續攀升，這主要是由於肥胖、荷爾蒙波動和糖尿病等風險因素的綜合影響。病例數的激增凸顯了對先進診斷和治療方法的迫切需求，從而推動了市場的擴張。隨著人們對子宮內膜癌的認知不斷提高，以及對有效醫療解決方案需求的日益成長，預計該市場將迎來顯著成長，這也反映了與疾病相關的持續挑戰。

全球子宮內膜癌市場的阻礙因素

全球子宮內膜癌市場面臨的主要挑戰是治療費用高昂和醫療資源匱乏，尤其是在發展中地區。手術、化療和放射線治療等治療費用高昂，令許多患者難以負擔，導致他們無法獲得所需的治療。對於那些醫療保險覆蓋範圍有限或經濟資源不足的患者而言，情況更為嚴峻，造成治療選擇上的不平等，並阻礙了疾病的整體管理。確保人人都能公平地獲得負擔得起的醫療保健仍然是該市場面臨的關鍵挑戰。

全球子宮內膜癌市場趨勢

目前，全球子宮內膜癌市場正經歷動態變化，其特點是製藥公司與研究機構之間開展了強而有力的合作和策略聯盟。這種協同作用旨在加速藥物研發，提高臨床試驗效率，這對於將創新療法推向市場至關重要。因此，人們越來越重視改進診斷技術和引入新型療法，以實現針對個別患者的個人化治療。這些進展有望顯著改善患者的治療效果，推動子宮內膜癌領域對有效治療方法的需求，最終改變癌症治療模式。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球子宮內膜癌市場規模（按癌症類型和複合年成長率分類）（2026-2033 年）

• 子宮內膜癌
  • 腺癌
  • 癌症肉瘤
  • 鱗狀細胞癌
  • 其他癌症類型
• 子宮肉瘤

全球子宮內膜癌市場規模（按治療類型和複合年成長率分類）（2026-2033 年）

• 外科手術
• 化療
• 放射線治療
• 荷爾蒙療法
• 標靶治療
• 免疫療法

全球子宮內膜癌市場規模（按診斷方法和複合年成長率分類）（2026-2033 年）

• 切片檢查
• 骨盆腔超音波
• 子宮鏡檢查
• 電腦斷層掃描
• 其他診斷方法

全球子宮內膜癌市場規模（依分期及複合年成長率分類）（2026-2033 年）

• 第一階段
• 第二階段
• 第三階段
• 第四階段

全球子宮內膜癌市場規模（按最終用途和複合年成長率分類）（2026-2033 年）

• 醫院
• 癌症中心
• 門診手術中心

全球子宮內膜癌市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• GlaxoSmithKline plc（GSK）（United Kingdom）
• Merck & Co., Inc.（United States）
• Notable Product：Keytruda（pembrolizumab）
• AstraZeneca plc（United Kingdom）
• Notable Product：Imfinzi（durvalumab）
• Novartis AG（Switzerland）
• Pfizer Inc.（United States）
• F. Hoffmann-La Roche AG（Switzerland）
• Bristol Myers Squibb Company（United States）
• Karyopharm Therapeutics Inc.（United States）
• Siemens Healthineers AG（Germany）
• Takeda Pharmaceutical Company Limited（Japan）
• Incyte Corporation（United States）
• Context Therapeutics Inc.（United States）
• Evergreen Therapeutics, Inc.（United States）
• Sysmex Corporation（Japan）
• Gilead Sciences, Inc.（United States）
• Johnson & Johnson（United States）
• AbbVie Inc.（United States）
• Sanofi SA（France）

結論與建議

Global Endometrial Cancer Market size was valued at USD 30.1 Billion in 2024 and is poised to grow from USD 31.57 Billion in 2025 to USD 46.3 Billion by 2033, growing at a CAGR of 4.9% during the forecast period (2026-2033).

The global endometrial cancer market is experiencing robust growth driven by rising incidence rates, heightened awareness, and enhanced healthcare infrastructure. Innovations in diagnostic methods, particularly molecular profiling and genetic testing, facilitate accurate and personalized treatment strategies. The emergence of targeted therapies, immunotherapies, and combination treatment approaches contributes to market expansion by improving efficacy and minimizing adverse effects compared to conventional treatments. Furthermore, advancements like genomic profiling and liquid biopsies support early detection efforts and customized therapy options. Nevertheless, obstacles such as high treatment costs, limited access to advanced healthcare facilities, and the necessity for effective early detection techniques pose significant challenges that must be addressed to alleviate the global endometrial cancer burden.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Endometrial Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Endometrial Cancer Market Segments Analysis

Global Endometrial Cancer Market is segmented by Cancer Type, Treatment, Diagnosis Method, Stage, End Use and region. Based on Cancer Type, the market is segmented into Endometrial carcinoma and Uterine sarcoma. Based on Treatment, the market is segmented into Surgery, Chemotherapy, Radiation therapy, Hormone therapy, Targeted therapy and Immunotherapy. Based on Diagnosis Method, the market is segmented into Biopsy, Pelvic Ultrasound, Hysteroscopy, CT Scan and Other Diagnosis Methods. Based on Stage, the market is segmented into Stage I, Stage II, Stage III and Stage IV. Based on End Use, the market is segmented into Hospitals, Cancer centers and Ambulatory surgical centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Endometrial Cancer Market

A significant factor propelling the global endometrial cancer market is the rising incidence of endometrial cancer across the globe. As one of the most prevalent gynecological cancers, its occurrence is on the upswing, largely due to a combination of risk factors like obesity, hormonal fluctuations, and diabetes. This surge in cases highlights the urgent need for advanced diagnostic and treatment options, boosting the market's expansion. As awareness regarding endometrial cancer grows and the demand for effective healthcare solutions increases, the market is poised for substantial growth, reflecting the ongoing challenges associated with this disease.

Restraints in the Global Endometrial Cancer Market

A notable challenge facing the global endometrial cancer market is the significant expense associated with treatment and the lack of accessibility to healthcare services, particularly in underdeveloped areas. The financial burden of treatments, such as surgeries, chemotherapy, and radiation therapy, can be quite high, preventing many patients from receiving the necessary care. This situation is exacerbated for individuals with limited health insurance coverage or insufficient financial resources, leading to disparities in treatment options and hindering the overall management of the disease. Ensuring equitable access to affordable care remains a critical issue within the market.

Market Trends of the Global Endometrial Cancer Market

The Global Endometrial Cancer market is currently experiencing a dynamic shift characterized by robust collaborations and strategic partnerships between pharmaceutical companies and research institutions. This synergy is focused on expediting drug development and enhancing clinical trial efficiency, which is critical for bringing innovative treatments to market. As a result, there is a growing emphasis on improved diagnostics and the introduction of novel therapies designed to tailor treatment to individual patient needs. These advancements are anticipated to significantly enhance patient outcomes, driving demand for effective solutions in the endometrial cancer space and ultimately transforming the landscape of cancer care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Endometrial Cancer Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Endometrial carcinoma
  • Adenocarcinoma
  • Carcinosarcoma
  • Squamous Cell Carcinoma
  • Other Types of Cancer
• Uterine sarcoma

Global Endometrial Cancer Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Surgery
• Chemotherapy
• Radiation therapy
• Hormone therapy
• Targeted therapy
• Immunotherapy

Global Endometrial Cancer Market Size by Diagnosis Method & CAGR (2026-2033)

• Market Overview
• Biopsy
• Pelvic Ultrasound
• Hysteroscopy
• CT Scan
• Other Diagnosis Methods

Global Endometrial Cancer Market Size by Stage & CAGR (2026-2033)

• Market Overview
• Stage I
• Stage II
• Stage III
• Stage IV

Global Endometrial Cancer Market Size by End Use & CAGR (2026-2033)

• Market Overview
• Hospitals
• Cancer centers
• Ambulatory surgical centers

Global Endometrial Cancer Market Size & CAGR (2026-2033)

• North America (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • US
  • Canada
• Europe (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• GlaxoSmithKline plc (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Notable Product: Keytruda (pembrolizumab)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Notable Product: Imfinzi (durvalumab)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Context Therapeutics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evergreen Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations